ClinicalTrials.gg
Active, not recruitingNCT07708272Updated Aug 7, 2026

QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

A Phase 1 interventional study of TQ05105 tablets and Placebo tablets in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Enrollment
2nd of 10
60 · median 28
Started
2026
with 3 others
Phase 1
7 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 2nd largest by enrollment, is one of 4 that started in 2026, is one of 7 in phase 1, and was the 10th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants.

Secondary Objectives:

To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT, RR, PR and QRS intervals) in healthy Chinese participants; To verify assay sensitivity by evaluating the effect of moxifloxacin on QTcF interval; To evaluate the safety and tolerability of single-dose TQ05105 in healthy Chinese participants; To characterize the pharmacokinetic (PK) characteristics of TQ05105 and its metabolite (TQ12550) after single administration of TQ05105 tablets in healthy Chinese participants.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical trial and sign the form; fully understand the trial content, procedures and potential adverse reactions; able to communicate well with the investigator and complete the study in accordance with the protocol requirements;
  2. Participants (including their partners) have no plans for pregnancy, sperm donation or egg donation from screening until 6 months after the last dose of study drug, and voluntarily adopt effective measures;
  3. Healthy participants aged 18 to 45 years (inclusive) at the time of signing the informed consent form, both male and female eligible;
  4. At screening, male participants weigh no less than 50.0 kg and female participants weigh no less than 45.0 kg. (BMI) = weight (kg) / height² (m²), within the range of 18.0 to 26.0 kg/m² (inclusive).

Exclusion criteria

Exclusion Criteria:

  1. History of severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematological, endocrine and metabolic, neoplastic, immune or psychiatric systems or any other medical conditions that may interfere with trial outcomes within the past 1 year or at present;
  2. History of any within 5 years before screening;
  3. count or below the lower limit of the reference range in complete blood count at screening;
  4. Any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
  5. Subjects with any condition that may affect the absorption, distribution, metabolism or excretion of the study drug (e.g., inability to swallow tablets) or who have undergone gastrointestinal resection that may interfere with drug absorption, distribution, metabolism or excretion;
  6. Risk factors for torsades de pointes (TdP) at screening, including but not limited to the history of: syncope of unknown origin; heart failure; myocardial infarction; angina pectoris; history of various electrolyte abnormalities (potassium, sodium, chloride, calcium, magnesium, etc.); bundle branch block; atrial fibrillation, atrial flutter, atrial premature beats, ventricular premature beats, non-sustained or sustained ventricular tachycardia; bradycardia or sick sinus syndrome; personal or family history of any cardiac conduction abnormality; personal or family history of long syndrome (LQTS); or family history of sudden cardiac death;
  7. to moxifloxacin or any fluoroquinolone antibacterial agents, TQ05105 or its , or history of multiple allergies (e.g., allergy to two or more substances, including drug allergy history, predisposition to skin rash, eczema, urticaria, asthma, etc.);
  8. Use of any strong or moderate inhibitors or inducers of , CYP2C9 and CYP2C19 enzymes within 4 weeks before screening (see Appendix 3 for details);
  9. Use of any prescription drugs (including that may cause QT/QTc interval prolongation / TdP), over-the-counter drugs, Chinese herbal medicines or dietary supplements (e.g., vitamins, calcium supplements, etc.) within 4 weeks before screening;
  10. Participation in any drug clinical trial and exposure to any product within 3 months before screening or within 5 half-lives of the drug (whichever is longer);
  11. Abnormal results of physical examination, vital signs, clinical laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis), chest radiograph (PA and lateral views), or abdominal ultrasound (liver, gallbladder, pancreas, spleen and kidneys) at screening that are judged by the investigator;
  12. 12-lead exceeding the following thresholds at screening or baseline: PR > 200 ms, QRS > 110 ms, HR \< 50 bpm or > 100 bpm, QTcF > 450 ms (for both males and females); or ECG abnormalities judged by the investigator to be clinically significant (e.g., atrioventricular block, torsades de pointes, other types of ventricular tachycardia, ventricular fibrillation and ventricular flutter, clinically significant T-wave changes, or any 12-lead ECG abnormalities that may affect the QTc interval);
  13. Positive test results for (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or Treponema pallidum antibody;
  14. (eGFR) \< 90 mL/min/1.73m² at screening;
  15. Average daily cigarette consumption of more than 5 cigarettes within 3 months before screening;
  16. History of substance abuse within 3 months before screening, or positive urine drug screen;
  17. Regular alcohol consumption within 3 months before screening, defined as more than 14 standard alcohol units per week (1 unit = 360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine), or positive breath alcohol test;
  18. Blood donation or blood loss ≥ 200 mL, or plasmapheresis within 4 weeks before screening;
  19. Consumption of any food or beverage containing alcohol (or positive breath alcohol test), grapefruit juice, coffee, tea, cola, or chocolate within 72 hours before dosing;
  20. Pregnant or lactating female participants, or positive blood pregnancy test or value above the , or female participants of who have had unprotected sexual intercourse within 2 weeks before screening;
  21. Strenuous exercise (e.g., marathon, weightlifting) within 2 weeks before screening;
  22. Any other condition considered by the investigator to make the participant unsuitable for the trial;
  23. Participants unable to complete the trial due to personal reasons.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    TQ05105 tablets 20 mg+Placebo tablets 10 mg

    4 tablets of 5 mg TQ05105 tablets plus 2 tablets of 5 mg matching placebo tablets, delivering a total TQ05105 dose of 20 mg.

    Drug: TQ05105 tablets · Drug: Placebo tablets

  • Experimental
    TQ05105 tablets 30 mg

    6 tablets of 5 mg TQ05105 tablets, with a total TQ05105 dose of 30 mg.

    Drug: TQ05105 tablets

  • Placebo comparator
    Placebo tablets 30 mg

    6 tablets of 5 mg TQ05105 matching placebo tablets, with a total placebo dose of 30 mg.

    Drug: Placebo tablets

  • Active comparator
    Moxifloxacin Hydrochloride tablets 0.4 g

    1 tablet of 0.4 g Moxifloxacin Hydrochloride Tablets, serving as an open-label positive control drug.

    Drug: Moxifloxacin Hydrochloride Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Fridericia Placebo-Corrected Change from Baseline in QTc Interval (ΔΔQTcF)

    Placebo \& baseline corrected ΔQTcF, core indicator to assess drug effect on ventricular repolarization.

    Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

Secondary outcomes

  1. Heart Rate (HR)

    Holter-derived heart rate

    Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  2. PR interval (PR)

    PR interval obtained via continuous Holter ECG monitoring

    Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  3. RR interval (RR)

    Holter-recorded RR interval

    Time frame: 60 minutes, 45 minutes and 30 minutes before dosing on Day 1 of each period, and 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  4. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  5. Area under the plasma concentration-time curve ( AUC0-t)

    The area enclosed by the blood concentration curve to the timeline

    Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  6. Plasma clearance (CL/F)

    How much of the plasma is cleared per unit of time

    Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  7. Plasma elimination half-life (t1/2)

    The time it takes for the terminal phase blood concentration to drop by half

    Time frame: 1 hours before dosing, and at 15 minutes, 30 minutes, 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours after dosing.

  8. Adverse event rate

    The occurrence of all adverse events (AEs), and serious adverse events (SAEs).

    Time frame: 26 days after the first dose

  9. Hematology

    Abnormal hematology

    Time frame: 26 days after the first dose

  10. Serum biochemistry

    Abnormal serum biochemistry

    Time frame: 26 days after the first dose

  11. Coagulation

    Abnormal coagulation

    Time frame: 26 days after the first dose

  12. Urinalysis

    Abnormal urinalysis

    Time frame: 26 days after the first dose

  13. Blood pressure

    Abnormal blood pressure

    Time frame: 26 days after the first dose

  14. Pulse

    Abnormal pulse

    Time frame: 26 days after the first dose

  15. Body temperature

    Abnormal body temperature

    Time frame: 26 days after the first dose

07

Study locations

1 site
  • PKU Care Luzhong Hospital
    Zibo, Shandong 255499, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07708272
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 30, 2026
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion